How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,149 results for

Bullous Pemphigoid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non-bullous pemphigoid. Full Text available with Trip Pro

Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non-bullous pemphigoid. Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering disease. Patients occasionally present with a clinical picture of pruritus/urticaria alone for months and do not even develop blisters over time. Only few studies have investigated this subgroup of non-bullous pemphigoid (NBP).To evaluate the demographic and clinical characteristics of BP patients

2019 Journal of the European Academy of Dermatology and Venereology

2. Bullous pemphigoid

Bullous pemphigoid Bullous pemphigoid - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Bullous pemphigoid Last reviewed: February 2019 Last updated: November 2018 Summary Typically occurs in older people and has a distinctive clinical appearance. There are several clinical variants, 1 of which occurs in childhood. In the prodromal, non-bullous phase, pruritus of variable intensity may be accompanied by eczematous (...) of existing blisters and erosions, and to control the associated pruritus. Topical and systemic corticosteroids, as well as other immunosuppressive and anti-inflammatory agents, are used. Definition Bullous pemphigoid is a chronic, acquired autoimmune blistering disease characterised by auto-antibodies against hemidesmosomal antigens, resulting in the formation of a sub-epidermal blister. Liu Z. Are anti-BP180 IgG1 or IgG4 autoantibodies pathogenic? J Invest Dermatol. 2002;119:989-990. History and exam

2018 BMJ Best Practice

3. Bullous pemphigoid

Bullous pemphigoid Bullous pemphigoid - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Bullous pemphigoid Last reviewed: February 2019 Last updated: November 2018 Summary Typically occurs in older people and has a distinctive clinical appearance. There are several clinical variants, 1 of which occurs in childhood. In the prodromal, non-bullous phase, pruritus of variable intensity may be accompanied by eczematous (...) of existing blisters and erosions, and to control the associated pruritus. Topical and systemic corticosteroids, as well as other immunosuppressive and anti-inflammatory agents, are used. Definition Bullous pemphigoid is a chronic, acquired autoimmune blistering disease characterised by auto-antibodies against hemidesmosomal antigens, resulting in the formation of a sub-epidermal blister. Liu Z. Are anti-BP180 IgG1 or IgG4 autoantibodies pathogenic? J Invest Dermatol. 2002;119:989-990. History and exam

2018 BMJ Best Practice

5. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid. Full Text available with Trip Pro

Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid. Dipeptidyl peptidase-4 inhibitors (DPP-4i or gliptins) increase the risk of developing bullous pemphigoid (BP). To clarify, whether gliptin-associated BP has special features, we analyzed the clinical, histopathological and immunological features of 27 BP patients, 10 of which previously used gliptin medication. Compared to those who had not previously received gliptins, subjects who

2019 Acta Dermato-Venereologica

6. Circulating Bullous Pemphigoid Autoantibodies in the Setting of Negative Direct Immunofluorescence Findings for Bullous Pemphigoid: A Single-Center Retrospective Review. (Abstract)

Circulating Bullous Pemphigoid Autoantibodies in the Setting of Negative Direct Immunofluorescence Findings for Bullous Pemphigoid: A Single-Center Retrospective Review. Bullous pemphigoid (BP) autoantibody levels are generally elevated in patients with BP but can be present nonspecifically in patients without BP.To analyze elevated levels of BP180 or BP230 autoantibodies and clinical findings for patients who had negative direct immunofluorescence (DIF) studies.We retrospectively reviewed

2019 Journal of American Academy of Dermatology

7. Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Lite Full Text available with Trip Pro

Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Lite An 83-year-old patient developed erosions and a blister of the gingival mucous membrane, 6 months after discontinuation of the anti-programmed death-1 (anti PD-1) pembrolizumab therapy administered for 10 months for a metastatic melanoma (...) events. MMP describes a group of chronic, inflammatory, mucous membrane-predominant, subepithelial auto-immune blistering diseases. It is clinically distinct from bullous pemphigoid another autoimmune blistering disease but shares some immunological similarities with it. Twenty-nine cases of bullous pemphigoid associated with anti PD-1/PD-L1 have been reported in the literature and one of MMP. Here, we described the case of a MMP developed after pembrolizumab and discussed the accountability of anti

2018 Frontiers in medicine

8. Disseminated Nocardiosis with retinal abscess in a patient treated for bullous pemphigoid Full Text available with Trip Pro

Disseminated Nocardiosis with retinal abscess in a patient treated for bullous pemphigoid To report a case of disseminated Nocardiosis with retinal and intracranial lesions.A 49-year-old woman immunosuppressed because of treatment given for bullous pemphigoid presented with altered mental status and multiple intracranial lesions on imaging. The patient was found to have multiple retinal lesions in both eyes, including a subretinal abscess in the right eye. The patient underwent brain biopsy

2018 American journal of ophthalmology case reports

9. Neurodegenerative disorders, bullous pemphigoid and psoriasis: a comparative study in ethnic Poles indicates that Parkinson’s disease is more relevant to bullous pemphigoid Full Text available with Trip Pro

Neurodegenerative disorders, bullous pemphigoid and psoriasis: a comparative study in ethnic Poles indicates that Parkinson’s disease is more relevant to bullous pemphigoid Bullous pemphigoid (BP) is an autoimmune blistering dermatosis of the elderly with autoimmunity to hemidesmosomal proteins, BP180 and BP230, which are expressed also in neuronal tissue.The aim here was to retrospectively compare the prevalence of neurodegenerative disorders (ND), particularly Parkinson's disease (PD

2017 Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

10. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetra Full Text available with Trip Pro

A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetra Bullous pemphigoid (BP) is an autoimmune blistering skin disorder with increased morbidity and mortality in the elderly.To evaluate the effectiveness, safety and cost-effectiveness of a strategy of initiating BP treatment with oral doxycycline

2017 Health technology assessment (Winchester, England) Controlled trial quality: predicted high

11. Increased frequency of multiple sclerosis among bullous pemphigoid patients. A population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. (Abstract)

Increased frequency of multiple sclerosis among bullous pemphigoid patients. A population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Bullous pemphigoid (BP) is a disease of the elderly and may be associated with neurological and cardiovascular diseases and diabetes. Mortality rates strongly exceed those of the background population.To investigate the frequency of comorbidities and their temporal relation to BP.A register-based matched-cohort study

2017 British Journal of Dermatology

12. Minocycline decreases Th2 chemokines from M2 macrophages: possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs. Full Text available with Trip Pro

Minocycline decreases Th2 chemokines from M2 macrophages: possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs. Minocycline/tetracycline is clinically used for the treatment of bullous pemphigoid (BP), and its clinical benefits are superior to those of prednisolone when considering adverse events. Although the clinical benefits of minocycline/tetracycline are well known, its immunosuppressive mechanisms are still unclear. In this study, we

2018 Experimental Dermatology

13. Insect Bite-Like Reaction with Bullous Lesions Mimicking Bullous Pemphigoid in a Patient with Chronic Lymphocytic Leukemia Full Text available with Trip Pro

Insect Bite-Like Reaction with Bullous Lesions Mimicking Bullous Pemphigoid in a Patient with Chronic Lymphocytic Leukemia Patients with chronic lymphocytic leukemia (CLL) rarely exhibit an exaggerated insect bite-like reaction without a history of an arthropod bite. We report a case of an insect bite-like reaction in a 74-year old man with CLL. The patient presented with a 2-year history of recurrent itchy erythematous patches and blisters on the whole body. He had been diagnosed with CLL 2 (...) of insect bite-like reaction associated with CLL as a distinct disease entity that is similar to insect bite or bullous pemphigoid.

2018 Annals of dermatology

14. Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study (Abstract)

Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study Activation of blood coagulation has been demonstrated in bullous pemphigoid (BP), a rare autoimmune blistering disease, potentially leading to a prothrombotic state. In order to evaluate the incidence of venous thromboembolism (VTE) in BP, a cohort study was carried out on 432 BP patients (59% females; median age 76 years, interquartile (...) range [IQR]: 68-82). At diagnosis, autoimmune bullous skin disorder intensity score (ABSIS) was calculated. VTE incidence was standardised with rates of the general population. Multivariable Cox proportional hazard model was used to estimate the hazard ratio of VTE according to ABSIS and concomitant risk factors. During a median follow-up of 4.2 years, 31 objectively-diagnosed VTE events were recorded. The incidence rate of VTE (per 1000 patient-years) was 17.2 overall (95% confidence interval [CI

2015 EvidenceUpdates

15. Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180. Full Text available with Trip Pro

Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180. The study by Plaquevent et al. strongly supports the recent discovery that the use of gliptins is a risk factor for bullous pemphigoid (BP). However, regarding the phenotype of gliptin-associated BP and the necessity of gliptin withdrawal, clinical data remain scarce. We predict that future studies of gliptin-associated BP will offer valuable information concerning

2019 Journal of Investigative Dermatology

16. Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceous. (Abstract)

Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceous. The BIOCHIP is a novel multiplex indirect immunofluorescence technique used in the serological diagnosis of bullous pemphigoid and pemphigus. The BIOCHIP method combines the screening of autoantibodies and target antigen specific substrates in a single miniature incubation field.To evaluate the diagnostic accuracy of the new immunofluorescence BIOCHIP multiplex tool in pemphigus (...) and bullous pemphigoid.For the validation of the BIOCHIP, sera from patients with BP (n=38), PF (n=8), and PV (n=23) were used. In addition, sera from disease control patients (n=63) and healthy volunteers (n=39) were used. The multiplex BIOCHIP and direct immunofluorescence (DIF) was performed for all BP, PF and PV patients. Additional IIF was performed on patients with BP and ELISA was performed on patients with pemphigus.The BIOCHIP mosaic showed a sensitivity of 86.8% and specificity of 85% for BP180

2019 Journal of the European Academy of Dermatology and Venereology

17. Ex vivo confocal laser scanning microscopy for bullous pemphigoid diagnostics: new era in direct immunofluorescence? (Abstract)

Ex vivo confocal laser scanning microscopy for bullous pemphigoid diagnostics: new era in direct immunofluorescence? Ex vivo confocal laser scanning microscopy (ex vivo CLSM) is a novel diagnostic method allowing rapid, high-resolution imaging of excised skin samples. Furthermore, fluorescent detection is possible using fluorescent-labeled antibodies.To assess the applicability of ex vivo CLSM in the detection of basement membrane (BM) fluorescence in bullous pemphigoid (BP) and to compare its

2019 Journal of the European Academy of Dermatology and Venereology

18. Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid. (Abstract)

Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid. Deposition of autoantibodies (α-BP180/230) and complement along the dermal-epidermal-junction is a hallmark of bullous pemphigoid (BP) and was shown to be important for pathogenesis. Given the adverse effects of standard treatment (glucocorticoids, immunosuppressants), there is an unmet need for safe and effective therapies. In this Phase 1 trial, we

2019 Journal of Investigative Dermatology

19. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. (Abstract)

Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis. There have been a number of case reports and small clinical series reporting the potential association between dipeptidyl peptidase-4 inhibitors (DPPIs) for diabetes and the onset of bullous pemphigoid (BP). The aim of this study was to assess the association between DPPI use and BP, and whether this varied according to DPPI type.We performed a systematic review and meta-analysis according (...) and BP (OR 1.29, 95%CI 0.79-2.08, P = 0.31). Subgroup analysis demonstrated that the association between DPPI use and BP remained significant in males (OR 2.35, 95% CI 1.46-3.78, P = 0.0005) and females (OR 1.88, 95%CI 1.10-3.22, P = 0.02).Limitations were that studies reviewed were retrospective by design which are susceptible to bias and lack of randomisation. Our adjusted analysis supports a significant association between DPPI use and onset of bullous pemphigoid. Vildagliptin had the highest odds

2019 Australasian Journal of Dermatology

20. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. (Abstract)

Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Bullous pemphigoid and pemphigus constitute two major autoimmune blistering diseases (AIBD) with complicated disease pathomechanisms involving a multitude of cytokines and immunological pathways. The purpose of our literature review of the cytokines and chemokines involved in these AIBDs was to allow for a meta-analysis of numerous studies detailing differential cytokine and chemokine changes

2019 Autoimmunity reviews

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>